Limits...
Symptom relief effect of palliative high dose rate intracavitary radiotherapy for advanced esophageal cancer with dysphagia.

Yamashita M, Yamashita H, Shibata S, Okuma K, Nakagawa K - Oncol Lett (2015)

Bottom Line: In consideration of the individual efficacy of the treatment, the maximum number of repeated ICRT fractions was four (median, 1.7 times).Furthermore, pain was the most frequent side-effect of the esophageal ICRT and no patients exhibited severe complications.Thus, esophageal ICRT at a dose of 6 Gy/fraction may present an effective strategy for relieving the symptom of dysphagia in cases of advanced esophageal cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.

ABSTRACT

Intracavitary radiotherapy (ICRT) for the palliative treatment of advanced esophageal cancer with dysphagia is currently performed at the University of Tokyo Hospital (Tokyo, Japan). In the present study, 24 patients exhibiting advanced esophageal cancer with dysphagia received palliative ICRT. ICRT, which was delivered 5 mm below the esophageal mucous membrane, with the exception of one case, was administered at a dose of 6 Gy/fraction. Specific patients additionally underwent definitive or palliative external beam radiation therapy for esophageal cancer a minimum of three months prior to ICRT. The effect of treatment on symptom alleviation was examined by comparing the dysphagia score prior to and following ICRT, with the patients' medical records and a questionnaire used to calculate a dysphagia score ranging from zero (no dysphagia) to four (total dysphagia). In consideration of the individual efficacy of the treatment, the maximum number of repeated ICRT fractions was four (median, 1.7 times). A trend in the improvement of the symptom of dysphagia was observed in response to esophageal ICRT, with the average dysphagia score markedly decreasing from 2.54 to 1.65, however, the difference was not significant (P=0.083). Furthermore, pain was the most frequent side-effect of the esophageal ICRT and no patients exhibited severe complications. Thus, esophageal ICRT at a dose of 6 Gy/fraction may present an effective strategy for relieving the symptom of dysphagia in cases of advanced esophageal cancer.

No MeSH data available.


Related in: MedlinePlus

Duration of dysphagia in 15 patients, according to question number two of the questionnaire (y-axis indicates the number of patients).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4356424&req=5

f5-ol-09-04-1747: Duration of dysphagia in 15 patients, according to question number two of the questionnaire (y-axis indicates the number of patients).

Mentions: In addition, the duration time of dysphagia indicated in Fig. 5 was determined using data from question two of the questionnaire. The duration of dysphagia was approximately one week in three patients, two to three weeks in four patients, and approximately one, two to three, four to five and longer than five months in two patients, respectively. In the patient with the maximal reaction, the duration of dysphagia was >10 months, with continuing improvement observed until the completion of follow-up.


Symptom relief effect of palliative high dose rate intracavitary radiotherapy for advanced esophageal cancer with dysphagia.

Yamashita M, Yamashita H, Shibata S, Okuma K, Nakagawa K - Oncol Lett (2015)

Duration of dysphagia in 15 patients, according to question number two of the questionnaire (y-axis indicates the number of patients).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4356424&req=5

f5-ol-09-04-1747: Duration of dysphagia in 15 patients, according to question number two of the questionnaire (y-axis indicates the number of patients).
Mentions: In addition, the duration time of dysphagia indicated in Fig. 5 was determined using data from question two of the questionnaire. The duration of dysphagia was approximately one week in three patients, two to three weeks in four patients, and approximately one, two to three, four to five and longer than five months in two patients, respectively. In the patient with the maximal reaction, the duration of dysphagia was >10 months, with continuing improvement observed until the completion of follow-up.

Bottom Line: In consideration of the individual efficacy of the treatment, the maximum number of repeated ICRT fractions was four (median, 1.7 times).Furthermore, pain was the most frequent side-effect of the esophageal ICRT and no patients exhibited severe complications.Thus, esophageal ICRT at a dose of 6 Gy/fraction may present an effective strategy for relieving the symptom of dysphagia in cases of advanced esophageal cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.

ABSTRACT

Intracavitary radiotherapy (ICRT) for the palliative treatment of advanced esophageal cancer with dysphagia is currently performed at the University of Tokyo Hospital (Tokyo, Japan). In the present study, 24 patients exhibiting advanced esophageal cancer with dysphagia received palliative ICRT. ICRT, which was delivered 5 mm below the esophageal mucous membrane, with the exception of one case, was administered at a dose of 6 Gy/fraction. Specific patients additionally underwent definitive or palliative external beam radiation therapy for esophageal cancer a minimum of three months prior to ICRT. The effect of treatment on symptom alleviation was examined by comparing the dysphagia score prior to and following ICRT, with the patients' medical records and a questionnaire used to calculate a dysphagia score ranging from zero (no dysphagia) to four (total dysphagia). In consideration of the individual efficacy of the treatment, the maximum number of repeated ICRT fractions was four (median, 1.7 times). A trend in the improvement of the symptom of dysphagia was observed in response to esophageal ICRT, with the average dysphagia score markedly decreasing from 2.54 to 1.65, however, the difference was not significant (P=0.083). Furthermore, pain was the most frequent side-effect of the esophageal ICRT and no patients exhibited severe complications. Thus, esophageal ICRT at a dose of 6 Gy/fraction may present an effective strategy for relieving the symptom of dysphagia in cases of advanced esophageal cancer.

No MeSH data available.


Related in: MedlinePlus